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Background: Skeletal metastases represent an underappreciated site of metastasis in pa-
tients with pancreatic cancer. Previous reports have estimated the prevalence to range from
5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as er-
lotinib, there has been a modest increase in survival in patients with advanced pancreatic
cancer. As such, it is anticipated that previously uncommon occurrences such as skeletal
metastases will become more frequent.
Patients and Methods: Retrospective chart review was conducted at two academic insti-
tutions to identify pancreatic cancer patients with skeletal metastases over a two-year period.
Results: Seven patients were identified from a database of 323 patients (2.2 percent). All
patients had advanced disease and had received prior systemic therapy (range: 1-4 lines,
median: 2 lines). Approximately half (57.1 percent) of the patients were symptomatic from
their skeletal metastases. The most common sites of skeletal metastases were vertebrae
(100 percent), hips (57.1 percent), and ribs (57.1 percent). Both blastic and lytic lesions
were noted, with a predominance of blastic lesions (71.4 percent). A majority of patients
(71.4 percent) received bisphosphonates as part of their care.
Discussion: Skeletal metastases are an uncommon but clinically important occurrence in
patients with pancreatic cancer. Clinicians caring for patients with pancreatic cancer should
be alert regarding skeletal metastases, due to the morbidity it can cause for these patients
(e.g., back pain, fractures, etc.).
INTRODUCTION
The usual sites of metastases in pan-
creatic cancer are the liver and peritoneal
cavity. Other less common sites are the
lung, bone, and brain. Unusual sites such
as muscle, skin, heart, pleura, stomach, um-
bilicus, kidney, appendix, spermatic cord,
and prostate have also been reported [1-10].
*To whom all correspondence should be addressed: M. Wasif Saif, MD,Associate Professor,
Division of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520; E-mail:
wasif.saif@yale.edu.
†Abbreviations: PET, positron emission topographic; VEGF, vascular endothelial growth fac-
tor; PTHrP, parathyroid hormone-related protein; TGF-β, transforming growth factor beta; IL-
11, interleukin-11.Skeletal metastases from pancreatic
cancer have thus far been considered an in-
frequent occurrence.
The first case of pancreatic cancer with
skeletalmetastases wasdescribedinRussian
literature in 1963 [11].Although the true in-
cidence of skeletal metastases in patients
with pancreatic cancer is not known, it is felt
to be between 5 percent to 20 percent [12-
13]. There appears to be some suggestion
that the association is higher in patients who
have a primary that is in the tail of the pan-
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Table 1: Characteristics of Pancreatic Cancer Patients with Skeletal Metastases
Age
Sex
Stage at Initial
Diagnosis of
Cancer
Symptomatic vs.
Asymptomatic
BoneMetastases:
Sites of bone
metastases
Vertebrae
Hips
Ribs
Upper Extremities
Lower Extremities
Skull
Nature of Lesions
Bisphosponate
Use
Time Between
Initial Diagnosis
and Development
of Metastases
Survival Since
Diagnosis of
Bone Metastases
Survival Since
Initial Diagnosis
of Cancer
Number of Other
Metastatic Sites
Sites of Other
Metastases
Liver
Peritoneum
Lungs
Lymph Nodes
Kidney
Number of Lines
of Systemic
Chemotherapy
Patient B
70
Male
IV
Symptomatic
+
+
+
+
Blastic
Yes
8.5 months
Alive
Alive
1
+
2
Patient D
53
Male
III
Asymptomatic
+
+
Blastic
Yes
32 months
9 months
41 months
3
+
+
+
2
Patient C
62
Female
IV
Asymptomatic
+
+
+
Blastic
Yes
2.3 months
6.6 months
8.9 months
2
+
2
Patient F
59
Male
IV
Asymptomatic
+
Lytic
No
5.5 months
3.5 months
9 months
1
+
1
Patient G
57
Male
IV
Symptomatic
+
+
+
+
+
+
Blastic
No
2 months
0.3 month
4.25 months
3
+
+
+
1
Patient E
74
Female
IV
Symptomatic
+
+
Unknown
Yes
4.25 months
1.75 months
6 months
1
+
1
Patient A
58
Female
III
Symptomatic
+
Blastic
Yes
17.3 months
2 months
19.3 months
2
+
+
4creas [13]. Both osteolytic and osteoblastic
lesionshavebeendescribed.Skeletalsurveys
using standard roentgenograms, CT scans,
MRIs, and positron emission topographic
(PET†) scans have been used to detect the
presence of skeletal metastases in pancreatic
cancer [14-21]. No imaging modality ap-
pears to have a superior detection rate. How-
ever, when used in conjunction, the rates of
detection may be much higher. Early detec-
tion of skeletal metastases that are asympto-
matic may be achieved through the serial
measurement of C-telopeptide [13].
Bone pain, pathological fractures, and
hypercalcemia are possible sequelae of
skeletal metastases. Unusual symptoms such
as bilateral hearing loss associated with in-
volvement of the temporal bone have been
reported [22-23].Although the pathogenesis
of skeletal metastasis in pancreatic cancer
remains unknown, preliminary data suggests
that cytokines such as interleukin-6 (IL-6),
vascular endothelial growth factor (VEGF),
and parathyroid hormone-related protein
(PTHrP) may play a pivotal role in the
growth of pancreatic cancer in bone [13].
Extrapolating findings from other tumor
types, it is conceivable that other factors that
stimulate osteoclastic bone resorption such
as transforming growth factor beta (TGF-β),
interleukin-11 (IL-11), and matrix metallo-
proteinases may be involved as well [24].
Micrometastasesassociatedwithpancre-
atic adenocarcinoma have been found in the
bone marrow of patients. It is unclear if they
represent pre-clinical bone metastases [25].
PATIENTS AND METHODS
A retrospective chart review was con-
ducted at Scottsdale Clinical Research Insti-
tute, which serves as the clinical site for the
Translational Genomics Research Institute,
and Yale University Medical Center from
July 2005 to December 2007. Patients with
pancreatic cancer seen at these two institu-
tions over a two-year period were identified,
and those who had skeletal metastases were
reviewed. Both their demographic and clin-
ical details were tabulated. Only descriptive
statistics were used to summarize the data.
RESULTS
We identified seven cases (among 323
reviewed,prevalence2.2percent)ofpatients
withpancreaticcancerwhodevelopedskele-
tal metastases during the course of their dis-
ease (Table 1). The demographics were
representativeofpatientswithadvancedpan-
creatic cancer (age: median 59 years, range
57-70; males 4 [57.1 percent]/females 3
[48.3 percent]; race: Caucasian 7 [100 per-
cent]). All patients had advanced disease
(stage III: 2 [28.6 percent], stage IV: 5 [71.4
percent])atthetimeoftheirinitialdiagnoses.
The time to development of skeletal metas-
tases was variable and ranged from two to
17.3 months (median: 5.5 months). Patients
with stage III disease at initial diagnosis ap-
parentlyhadalongertimetodevelopmentof
skeletal metastases(range: 17.3-32 months),
compared to patients with stage IV disease
at initial diagnosis (range: 2-8.5 months). In
this case series, four of seven patients (57.1
percent) had symptomatic disease.The most
common site of skeletal metastasis was the
vertebrae (seven of seven patients [100 per-
cent]). Sites such as the hips and ribs were
somewhatlessprevalent(fourofsevencases
each [57.1 percent]); whereas, sites such as
the upper and lower extremities, skull, and
face were much less common. Both blastic
(Figures 1 and 2) and lytic lesions were seen
inthesepatients.However, thereappeared to
be a predominance of blastic lesions (five of
seven [71.4 percent]) in these patients. All
patientshadatleastoneothersiteofmetasta-
tic disease (range: 1-3, median: 2) with the
liver being most common extra-skeletal site
(six of seven [85.7 percent]). A majority of
patients(fiveofseven[71.4percent])hadre-
ceived bisphosphonates as part of their care.
All patients had received prior systemic
chemotherapy (range: 1-4 lines, median: 2
lines).
DISCUSSION
With the advent of the use of novel
agents such as erlotinib in conjunction with
more widely used agents such as gemc-
itabine, modest improvements of survival in
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carcinoma have been achieved [26,27]. De-
spite this, it appears there has not been a
considerable increase in the prevalence of
patients with pancreatic cancer developing
skeletal metastases. In our study, the inci-
dence may be low, as only symptomatic
bone metastases were detected. It is possible
that many more clinically silent metastases
would have been detected if we perform a
cross-sectional imaging. Most patients in
our review had restaging preformed (CT
scan) every eight to nine weeks, and no in-
cidental bone disease was noticed in the ra-
diological reports. PET/CT may be a useful
tool in detecting bone metastases as found
in two of our patients. A rigorous imaging
follow-up in all patients likely would reveal
many more metastases. Nevertheless, it re-
mains to be a clinically significant problem
that can be particularly complicated by the
fact that symptomatic presentation mistak-
enly might be thought to be a result of the
underlying primary malignancy (e.g., back
pain).
The patients identified in this case se-
ries are representative of patients with ad-
vanced pancreatic cancer in their
demographic characteristics. Survival from
the time of diagnosis of skeletal metastases
can be quite variable in this group of patients
(range: 0.3-9 months), and as such, the case
for the benefit of therapies such as bisphos-
phonates would have to be on a case-by-case
basis. It would be evident that bisphospho-
nates likely would benefit those patients
who would have a better performance status,
stage III vs. stage IV disease at the time of
diagnosis of skeletal metastases, given that
these have been shown to be factors associ-
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Figure 1. Positron Emission Tomography/Computed Tomography (PET/CT) scan of pa-
tient with metastatic pancreatic adenocarcinoma reveals multiple areas of skeletal involve-
ment most notably left frontal calvarium, spine, ribs, bilateral humeri, and pelvis.ated with prolonged overall survival. Of
note, none of the patients in this case series
experienced a skeletal metastatic complica-
tion such as cord compression or pathologi-
cal fracture. This possibly could be
attributed to the frequent use of bisphospho-
nates and the short duration of survival,
which potentially would have not allowed
such events to occur. Larger studies exam-
ining this question would need to be con-
ducted to draw any firm conclusions.
Interestingly, the spine (in the form of
vertebral metastases) was the most common
site of skeletal metastasis. Given this, back
pain can be a manifestation of pancreatic
cancer itself but clinicians should be alert
that it can occasionally be a presenting
symptom of skeletal metastases. Early diag-
nosis of skeletal metastases in such patients
may be paramount toward reducing morbid-
ity through early and effective interventions
such as the use of bisphosphonates [28].
Weagreethatconclusionsarelimitedbe-
cause of the retrospective nature of the study
and exact incidence cannot be given. How-
ever,atthesametime,thisstudysendsanim-
portant message: Clinicians treating patients
withpancreaticcancershouldconsiderevalu-
atingbonemetastasesinthesepatients,aspal-
liative radiation or even surgery can improve
the quality of life and may even prolong sur-
vival in patients with a single metastatic site.
CONCLUSIONS
The incidence of bone metastases sec-
ondary to adenocarcinoma of the exocrine
pancreas is unknown, since radiological
studies of the bones during life, routine bone
scintigrams, or extensive examination of the
skeleton at autopsy are rarely undertaken in
the absence of specific clinical indications.
Symptom-producingbonemetastasesarerel-
atively uncommon; a review of the literature
suggests that the vast majority are osteolytic
in nature with only a few isolated case re-
ports of purely blastic deposits. Our study
suggests that osteoblastic bone metastases
aremorecommonthangenerallyrecognized.
We described the clinical, radiological, and
pathological findings in these seven cases in
order to emphasize that the pancreas is a po-
tential source of bone metastases, especially
blastic. Clinicians caring for these patients
should be aware of this rare site of metat-
stases,andtheyalsoshouldconsiderthepan-
creas as a possible primary site in patients
who present initially with osteoblastic bone
deposits of unknown origin.
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Figure 2. Extensive involvement of spine by skeletal metastases as visualized by PET/CT
scan (sagittal view).REFERENCES
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